The Potential Impact of Heparanase Activity and Endothelial Damage in COVID-19 Disease.
ARDS
COVID-19
biomarker
endothelial dysfunction
heparan sulfate
heparanase
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Sep 2022
06 Sep 2022
Historique:
received:
30
06
2022
revised:
29
08
2022
accepted:
01
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
SARS-CoV-2 was first detected in 2019 in Wuhan, China. It has been found to be the most pathogenic virus among coronaviruses and is associated with endothelial damage resulting in respiratory failure. Determine whether heparanase and heparan sulfate fragments, biomarkers of endothelial function, can assist in the risk stratification and clinical management of critically ill COVID-19 patients admitted to the intensive care unit. We investigated 53 critically ill patients with severe COVID-19 admitted between March and April 2020 to the University Hospital RWTH Aachen. Heparanase activity and serum levels of both heparanase and heparan sulfate were measured on day one (day of diagnosis) and day three in patients with COVID-19. The patients were classified into four groups according to the severity of ARDS. When compared to baseline data (day one), heparanase activity increased and the heparan sulfate serum levels decreased with increasing severity of ARDS. The heparanase activity significantly correlated with the lactate concentration on day one (
Identifiants
pubmed: 36142913
pii: jcm11185261
doi: 10.3390/jcm11185261
pmc: PMC9502343
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : MA 7082/3-1
Organisme : START
ID : START 113/17
Références
Crit Care. 2020 Jun 16;24(1):353
pubmed: 32546188
Clin Appl Thromb Hemost. 2018 Nov;24(8):1223-1233
pubmed: 29996658
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Crit Care Med. 2011 Apr;39(4):702-10
pubmed: 21242795
Front Immunol. 2022 Jun 10;13:916512
pubmed: 35757776
Front Immunol. 2020 Oct 06;11:575047
pubmed: 33123154
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Int J Infect Dis. 2020 Nov;100:425-430
pubmed: 32896660
Nat Rev Cardiol. 2021 Mar;18(3):194-209
pubmed: 33214651
Shock. 2015 Dec;44(6):569-77
pubmed: 26529654
Biochemistry. 2004 May 4;43(17):4971-7
pubmed: 15109255
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Front Immunol. 2018 Sep 27;9:2147
pubmed: 30319615
PLoS One. 2015 May 29;10(5):e0127584
pubmed: 26024383
Pflugers Arch. 2007 Jun;454(3):345-59
pubmed: 17256154
Turk J Med Sci. 2020 Apr 15;50(SI-1):549-556
pubmed: 32293832
ASAIO J. 2020 May;66(5):472-474
pubmed: 32243267
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
PLoS One. 2015 Nov 23;10(11):e0143583
pubmed: 26600070
Cardiovasc Res. 2017 May 01;113(6):671-680
pubmed: 28453727
J Inflamm (Lond). 2019 Jan 15;16:1
pubmed: 30675131
Angiogenesis. 2020 Nov;23(4):611-620
pubmed: 32458111